AbbVie, Inc. (ABBV)
257.12
+2.12
(+0.83%)
USD |
NYSE |
Sep 11, 16:00
259.52
+2.40
(+0.93%)
Pre-Market: 05:59
AbbVie Enterprise Value : 518.65B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 518.65B |
| September 10, 2026 | 514.90B |
| September 09, 2026 | 507.68B |
| September 08, 2026 | 503.91B |
| September 04, 2026 | 517.48B |
| September 03, 2026 | 524.11B |
| September 02, 2026 | 526.78B |
| September 01, 2026 | 523.72B |
| August 31, 2026 | 517.41B |
| August 28, 2026 | 515.75B |
| August 27, 2026 | 520.47B |
| August 26, 2026 | 528.86B |
| August 25, 2026 | 533.97B |
| August 24, 2026 | 531.73B |
| August 21, 2026 | 532.50B |
| August 20, 2026 | 526.97B |
| August 19, 2026 | 534.29B |
| August 18, 2026 | 521.83B |
| August 17, 2026 | 506.65B |
| August 14, 2026 | 505.11B |
| August 13, 2026 | 507.52B |
| August 12, 2026 | 503.88B |
| August 11, 2026 | 506.23B |
| August 10, 2026 | 502.48B |
| August 07, 2026 | 499.07B |
| Date | Value |
|---|---|
| August 06, 2026 | 495.24B |
| August 05, 2026 | 499.35B |
| August 04, 2026 | 495.11B |
| August 03, 2026 | 497.41B |
| July 31, 2026 | 507.73B |
| July 30, 2026 | 519.16B |
| July 29, 2026 | 529.57B |
| July 28, 2026 | 529.39B |
| July 27, 2026 | 518.28B |
| July 24, 2026 | 522.61B |
| July 23, 2026 | 518.30B |
| July 22, 2026 | 511.90B |
| July 21, 2026 | 516.85B |
| July 20, 2026 | 512.04B |
| July 17, 2026 | 514.00B |
| July 16, 2026 | 513.82B |
| July 15, 2026 | 495.66B |
| July 14, 2026 | 496.84B |
| July 13, 2026 | 502.53B |
| July 10, 2026 | 502.67B |
| July 09, 2026 | 505.91B |
| July 08, 2026 | 510.91B |
| July 07, 2026 | 514.28B |
| July 06, 2026 | 514.48B |
| July 02, 2026 | 525.63B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Biogen, Inc. | 39.14B |
| Gilead Sciences, Inc. | 199.64B |
| Regeneron Pharmaceuticals, Inc. | 75.51B |
| Amgen, Inc. | 247.31B |
| REGENXBIO, Inc. | 606.74M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.604B |
| Revenue (Quarterly) | 16.99B |
| Total Expenses (Quarterly) | 13.39B |
| EPS Diluted (Quarterly) | 2.033 |
| Gross Profit Margin (Quarterly) | 74.71% |
| Profit Margin (Quarterly) | 21.21% |
| Earnings Yield | 1.38% |
| Operating Earnings Yield | 4.83% |
| Normalized Earnings Yield | 3.132 |